Imagine you are told you have prostate cancer. The doctor says it is low-grade for now. You might be a candidate for active surveillance, a plan to watch the cancer closely instead of treating it right away. But a new genetic score could help predict if that cancer is more likely to become aggressive over time.
This could change how men and their doctors make critical decisions. It adds a genetic layer to the picture, going beyond standard tests. The goal is to spot the cancers that need more attention early on.
Prostate cancer is one of the most common cancers in men. Millions of men live with a diagnosis. Many are placed on active surveillance. This means regular check-ups, blood tests, and biopsies. The hope is to avoid treatment if the cancer stays slow-growing. But some cancers can become more aggressive. Current tools do not always predict this well.
This uncertainty causes stress. It can lead to too much treatment or, in some cases, not enough. A better way to predict risk is needed. This is where the new genetic score comes in.
A New Way to Read the Genes
Doctors have long used a man’s age, family history, and PSA blood test to gauge risk. These are helpful but not perfect. The new research looks at a person’s germline DNA. This is the DNA you inherit from your parents. It is in every cell of your body.
The old way focused on the tumor itself. The new way looks at the genetic blueprint that may make a tumor more dangerous from the start. Think of it like this. The germline DNA is the soil. The tumor is the plant that grows in it. Some soil makes it easier for a tough, aggressive plant to take root. This score measures the quality of that soil.
The researchers created a "polygenic risk score" for aggressiveness. They call it PRSagg. It is a single number. It is calculated from 172 different genetic variants. Each variant has a tiny effect on its own. Together, they paint a bigger picture of risk. This is like adding up many small clues to solve a mystery.
The team used data from a huge group of men. They started with 38,688 men with prostate cancer from the Million Veteran Program. They looked for genetic patterns linked to high-grade, aggressive cancer at the time of diagnosis. They then tested their new score in other groups to see if it held up.
The score was tested in men who chose active surveillance. These are men with low-grade cancer who were not treated right away. The researchers wanted to see if the score could predict who would have a bad outcome later. This could mean the cancer growing, spreading, or coming back after treatment.
The results were clear. In the main group of veterans, a higher score was linked to a much higher chance of having aggressive cancer at diagnosis. The odds were about 53 percent higher for each standard deviation increase in the score. The score also predicted a higher risk of bad outcomes during active surveillance.
These findings were confirmed in two other large groups of men. One group came from the PRACTICAL Consortium, a global research effort. The other came from the ProtecT trial in the United Kingdom. In the ProtecT group, men on active surveillance with a high score had more than double the risk of metastasis, or cancer spreading to other parts of the body.
This suggests the score could be a useful tool. It could help a man with low-grade cancer understand his personal risk better. A high score might push a doctor and patient toward more frequent check-ups or even earlier treatment. A low score might offer more peace of mind.
This does not mean this treatment is available yet.
Experts in the field see this as a promising step. The score adds new information beyond standard risk factors. It could help refine who is a good candidate for active surveillance. It also opens a door to understanding how our inherited genes influence the behavior of a tumor once it forms.
What does this mean for you? If you or a loved one has prostate cancer, this is not a test you can get at your doctor’s office today. It is still in the research phase. But it points to a future where treatment is more personalized. It is a step toward matching the right treatment to the right person at the right time.
It is important to remember the limitations. This study looked at men who already had prostate cancer. The score is not meant to predict who will get cancer in the first place. The research was also based on data from specific groups, and more work is needed to see how it works for all men.
The road ahead involves more testing. Researchers need to see how this score performs in broader, more diverse populations. They also need to study if using this score actually improves patient outcomes over time. The goal is to turn this research into a tool that helps doctors and patients make better decisions.
For now, it offers a hopeful glimpse into the future of prostate cancer care. A future where a simple blood test for DNA could help guide one of the most personal and difficult decisions a man can make.